At the May 4, 2015, meeting, the Board approved a three-year, $14 million clinical trial designed to determine the best dose of aspirin to use to prevent heart attacks and strokes in people with heart disease. The study, called ADAPTABLE (Aspirin Dosing: A Patient-centric TrialAssessing Benefits and Long-term Effectiveness), will compare the benefits and harms of a low- and regular-strength daily dose of aspirin in patients diagnosed with heart disease. (Read more)

The Board also approved $14 million for the first demonstration project to be conducted using PCORnet, the National Patient-Centered Clinical Research Network, as well as plans for two more PCORnet demonstration projects totaling up to $29.5 million in support. (Read more)

All PCORI Board meetings are open to the public and registration to attend in-person meetings is not required. A live webinar was available for those unable to attend in person.

Each in-person public Board meeting includes a public comment period and individuals can register to provide comment on-site. Individuals unable to attend this meeting in person could provide comment via telephone. (Guidelines for Public Comments)

Meeting Materials

Teleconference Audio Recording

Approved Minutes of the May 4, 2015 Board Meeting